ClinicalTrials.gg
RecruitingNCT06111898BAMBIUpdated Nov 15, 2023

Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants

An observational study in Premature Birth, Cerebral Palsy and Neurodevelopmental Disorders, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 35 Weeks to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by University Hospital, Geneva · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
348
Ages
35 Weeks to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Premature Birth with a site in Switzerland — 12 open to participants now, 14 under way, none of them phase 3. Premature Birth · Switzerland.

Planned enrollment
5th of 14
348 · median 168
Started
2023
with 2 others
Observational
14 of 34
6 open now
Primary completion
2026-03
later than 7 of 13 live
Registered
25th of 34
by date
Lead sponsor
4 of 34
University Hospital, Geneva

Among the 34 studies in Premature Birth with a site in Switzerland, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2023, is one of 14 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 25th registered.

Premature Birth

2,556 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

12 of the 34 studies in Premature Birth with a site in Switzerland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 35 Weeks to 1 Year · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Premature Birth with a site in Switzerland, or all of them as a file.
02

Study summary

This project focuses on motor development, muscle growth and muscle activity. Using advanced, instrumented tests such as , the link between muscles and the movement characteristics will be studied. In addition, the evolution of these neuro-biomechanical determinants during the first year of life will be investigated. The examinations are planned for a group of high-risk infants (e.g. premature birth, cases of asphyxia, etc.) compared with a group of infants with typical development.

Read the detailed description

Background and rationale:

Prematurity and the associated causes of perinatal brain damage, as well as neonatal stroke and birth asphyxia, are major risk factors for neurodevelopmental disorders appearing from birth. In addition, these neuromotor disorders resulting from impaired brain development appear progressively over the course of the first year, affecting early movement and muscle growth. Therefore, early diagnosis and motor therapy are essential to improve long-term neurodevelopmental outcomes. However, in order to provide adequate strategies for these high-risk infants, it is crucial to identify the determinants of potential neuromotor deficits and their consequences on early motor behavior and developmental trajectory during the first year of life. A multimodal tool is needed to reveal the early neuro-biomechanical determinants of motor behavior in infants at high risk of neurodevelopmental disorders.

Objective(s):

  • Establishing a comprehensive multimodal tool for the assessment of neuro-biomechanical determinants of motor behavior in the first year of life in high-risk infants for neurodevelopmental impairments, further referred to as "advanced muscle and movement analysis (AMMA)"
  • Revealing early neuro-biomechanical determinants in high-risk infants covering the first year of life, including the time points in the neonatal period, at term age, at 3 months of (corrected) age, at 6 months of (corrected) age and at 12 months of (corrected) age, by using the AMMA

Outcome(s):

  • Using valid and reliable assessments within the protocol
  • Differences in neuro-biomechanical determinants between typically developing infants and high-risk infants at each time point.
  • Associations between the neuro-biomechanical determinants of motor behaviour in high-risk infants at each time point
  • Changes over time and interaction in the neuro-biomechanical determinants, and comparisons of these evolutions in high-risk infants with typical development.

Methodology

The current study is a national, single center (Geneva University Hospitals), observational study. This observational research will perform both cross-sectional and longitudinal data collection for cohorts of live-born infants.

The study population for this study will include children, i.e., neonates and infants between the age of 35-36 weeks of gestational age to 12 months of (corrected) age. Further, two main groups of children will be included, (a) typically developing (TD) children and (b) children at high-risk for neurodevelopmental impairments. The TD children will be used as a control group.

Procedure

Multiple study visits are planned for longitudinal data collection within the first year of life, i.e. a time of term age, at 3 months, at 6 months and 12 months of age. For the preterms, the investigators also plan to perform an assessment in the neonatal period, i.e. 35-36 weeks of gestation.

The duration of each visit session will be around 90 minutes per participant, providing also time for feeding moments and adaptation of the infant to the new environment. The visit in the neonatal period will be organized at the Neonatology Unit at HUG (Geneva University Hospitals). All visits from the term (equivalent) age will be organized in the Kinesiology Laboratory at the HUG.

In general, clinical data such as birth information, structural brain MRI and developmental assessments will be derived from the medical records.

The main procedures during each research visit are:

  1. Muscle assessment: using 3D freehand ultrasound technique, measuring the lower legs muscles, assessing muscle volume and length.
  2. Neuromotor development: using standardized scales, measuring the gross motor development and motor repertoire, assessing age-appropriate neuromotor development.
  3. Motor behavior: using surface electromyography and motion capture system, measuring spontaneous movements, assessing the movement quality and quantity
03

Conditions studied

  • Premature Birth
  • Cerebral Palsy
  • Neurodevelopmental Disorders
  • Brain Injuries
  • Nervous System Diseases

Keywords

  • Brain Imaging
  • General Movements
  • 3D freehand ultrasound
  • Muscle Morphology
  • Electromyography
04

Who can participate

Ages eligible
35 Weeks to 1 Year
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Preterm or a term born Infants with detectable risk factors for neurodevelopmental impairments will be enrolled

Eligibility criteria

Inclusion \& exclusion criteria for group of high-risk infants:

  • Infants born before or at 28 weeks of gestation
  • Infants born after 28 weeks of gestation and with brain injury.
  • A term birth with the clinical diagnosis of asphyxia (ischemic event with hypothermia) or neonatal stroke
  • Exclusion in case of genetic syndrome, or lower limb pathology (e.g. spina bifida)

Inclusion \& exclusion criteria for group of typically developing children:

  • Born at a gestational age above 37 weeks
  • Birth weight between P10 and P90
  • Head circumference between P10 and P90
  • Ph >7.1
  • Exclusion in case of genetic syndrome, lower limb pathology and/or brain malformations
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
348 participants (estimated)
Patient registry
No

Groups and cohorts

  • High-risk infants

    Other: No Intervention

  • Typically developing infants

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. General Movement Assessment

    Observation of general movements following the Prechtl's General Movement Assessment, interpreted by observing age-specific general movement components and extracting the Motor Optimality Score (0-12, the higher, the better outcome)

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age

  2. Hammersmith Neonatal/Infant Neurological Examination

    Neurological assessment for different domains such as muscle tone, postures, movements and reflexes . Resulting in total scores (0-78) which can be compared to norm values, and higher scores indicate better outcome.

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  3. Change in muscle morphology size

    The size of the lower leg muscles defined by freehand ultrasound

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  4. Change in muscle morphology length

    The length of the lower leg muscles defined by freehand ultrasound

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  5. Change in muscle activity

    Investigation of the muscle activity during spontaneous, whole body movements by using surface electromyography.

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  6. Change in motor behaviour

    Investigation movement quality/quantify during spontaneous, whole body movements by using reflective markers.

    Time frame: 35-36 weeks of gestation; term equivalent age, 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

Secondary outcomes

  1. Bayley Scales of Infant and Toddler Development - Version III

    Standardized neurodevelopmental test of gross and fine motor skills. Higher scores indicate better outcome.

    Time frame: 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  2. Alberta Infant Motor Scale (AIMS)

    Assessment of gross motor development during prone, supine, sitting and standing. Scores from 0-60. Higher scores indicate better outcome.

    Time frame: 3 months (corrected) age, 6 months (corrected) age and 12 months (corrected) age.

  3. Magnetic resonance imaging of the brain: classification

    Qualitatively assessment on the MRI classification system by Himmelman et al. to classify the nature of brain abnormalities.

    Time frame: up to 4 weeks post-term age

  4. Magnetic resonance imaging of the brain: quantification

    Qualitatively assessment on the MRI classification system by quantitative assessment using the Kidokoro scoring system to classify the extent of white and grey matter abnormalities. Total global scores were classified as normal (0-3), mild (4-7), moderate (8-11), or severe (≥12) brain abnormalities.

    Time frame: up to 4 weeks post-term age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Van den Broeck C. Neurodevelopmental outcome in very preterm and very-low-birthweight infants born over the past decade: a meta-analytic review. Dev Med Child Neurol. 2018 Apr;60(4):342-355. doi: 10.1111/dmcn.13675. Epub 2018 Jan 19. PubMed 29350401 ↗
  • Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007 Feb;109:8-14. Erratum In: Dev Med Child Neurol. 2007 Jun;49(6):480. PubMed 17370477 ↗
  • Gough M, Shortland AP. Could muscle deformity in children with spastic cerebral palsy be related to an impairment of muscle growth and altered adaptation? Dev Med Child Neurol. 2012 Jun;54(6):495-9. doi: 10.1111/j.1469-8749.2012.04229.x. Epub 2012 Feb 27. PubMed 22364585 ↗
  • De Beukelaer N, Vandekerckhove I, Huyghe E, Molenberghs G, Peeters N, Hanssen B, Ortibus E, Van Campenhout A, Desloovere K. Morphological Medial Gastrocnemius Muscle Growth in Ambulant Children with Spastic Cerebral Palsy: A Prospective Longitudinal Study. J Clin Med. 2023 Feb 16;12(4):1564. doi: 10.3390/jcm12041564. PubMed 36836099 ↗
  • Willerslev-Olsen M, Choe Lund M, Lorentzen J, Barber L, Kofoed-Hansen M, Nielsen JB. Impaired muscle growth precedes development of increased stiffness of the triceps surae musculotendinous unit in children with cerebral palsy. Dev Med Child Neurol. 2018 Jul;60(7):672-679. doi: 10.1111/dmcn.13729. Epub 2018 Mar 24. PubMed 29573407 ↗

Individual participant data

Plan to share: Yes — The data will be made available upon publication via online repository (yareta or zenodo)

Time frame: Upon publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2026, 29 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 29 months is below that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Nov 1, 2023
StartActual
Oct 10, 2023
Primary completionEst.
Mar 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111898
Responsible party
Stephane ARMAND (Professor, University Hospital, Geneva) — Principal investigator
First posted
Nov 1, 2023
Start date
Oct 10, 2023
Primary completion
Mar 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 15, 2023

Study contacts

Nathalie De Beukelaer, PhD
Contact
nathalie.debeukelaer@unige.ch
+41783033552
Stéphane Armand, PhD
Contact
stephane.armand@unige.ch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion